(Q33335584)

25 July 2017

title

Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer (English)

1 reference

25 July 2017

1 reference

1 reference

V Heinemann

1

1 reference

25 July 2017

H Wilke

2

1 reference

25 July 2017

H G Mergenthaler

3

1 reference

25 July 2017

M Clemens

4

1 reference

25 July 2017

H König

5

1 reference

25 July 2017

H J Illiger

6

1 reference

25 July 2017

M Arning

7

1 reference

25 July 2017

A Schalhorn

8

1 reference

25 July 2017

K Possinger

9

1 reference

25 July 2017

U Fink

10

1 reference

25 July 2017

publication date

1 November 2000

1 reference

25 July 2017

1 reference

25 July 2017

volume

11

1 reference

25 July 2017

issue

11

1 reference

25 July 2017

page(s)

1399-1403

1 reference

Pancreatic carcinoma in perspective. A continuing challenge

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026595525977

7 January 2021

Chemotherapy for pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026595525977

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026595525977

7 January 2021

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026595525977

7 January 2021

Phase II study of gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026595525977

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026595525977

7 January 2021

Activity of cisplatin in adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026595525977

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026595525977

7 January 2021

A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026595525977

7 January 2021

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1026595525977

7 January 2021

Identifiers

DOI

10.1023/A:1026595525977

1 reference

25 July 2017

1 reference